NEOS Investment Management LLC Sells 26,990 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

NEOS Investment Management LLC trimmed its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 60.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,693 shares of the company's stock after selling 26,990 shares during the period. NEOS Investment Management LLC's holdings in Mirum Pharmaceuticals were worth $732,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of MIRM. Jones Financial Companies Lllp lifted its position in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the period. Legato Capital Management LLC raised its stake in shares of Mirum Pharmaceuticals by 7.9% in the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company's stock worth $554,000 after buying an additional 977 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock valued at $421,000 after buying an additional 1,003 shares during the period. Rhumbline Advisers boosted its stake in Mirum Pharmaceuticals by 2.4% during the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company's stock valued at $2,196,000 after buying an additional 1,236 shares in the last quarter. Finally, Swiss National Bank grew its holdings in Mirum Pharmaceuticals by 1.9% during the fourth quarter. Swiss National Bank now owns 70,300 shares of the company's stock worth $2,907,000 after acquiring an additional 1,300 shares during the period.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the transaction, the senior vice president now owns 2,926 shares of the company's stock, valued at $125,291.32. The trade was a 20.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the sale, the chief executive officer now directly owns 119,359 shares of the company's stock, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,679 shares of company stock valued at $6,007,081. Corporate insiders own 22.87% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a report on Friday, February 28th. Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $58.20.

Mirum Pharmaceuticals Trading Down 2.8 %

Shares of Mirum Pharmaceuticals stock traded down $1.20 during trading on Friday, hitting $42.03. The stock had a trading volume of 641,598 shares, compared to its average volume of 518,440. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The company has a market capitalization of $2.06 billion, a PE ratio of -20.81 and a beta of 1.00. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $54.23. The stock has a 50 day simple moving average of $47.64 and a 200 day simple moving average of $43.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to analysts' expectations of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.